News | December 02, 2021
Molnupiravir, a step closer to approval in the fight against Covid-19
The U.S. FDA advisory committee voted 13-10 in favour of the oral antiviral medicine
The U.S. FDA advisory committee voted 13-10 in favour of the oral antiviral medicine
Oravax's vaccine technology is highly scalable for manufacturing and is easily transferable for wide scale logistical distribution, as there is no need for freezer storage
Preclinical data demonstrate sotrovimab, authorised in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron
Researchers observed that the Pfizer/BioNTech and Moderna vaccines were 78% and 73% effective in preventing Covid-19 infections, respectively
Vaccine effectiveness of complete vaccination against the moderate-to-severe disease was at 81 per cent
Booster dose is available to all residents aged 18+ and can be applied six months after the second dose of any other vaccine administered in UAE
The Omicron variant, which was designated a variant of concern by the World Health Organization (WHO), has more than 30 mutations in the spike protein alone
It’s a two-dose vaccine administered 28 days apart
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
One-shot Sputnik Light is a highly effective vaccine when used both on standalone basis and applied as a booster
Subscribe To Our Newsletter & Stay Updated
